CD99 is a 32 kDa surface glycoprotein that is involved in the migration of leukocytes, cell–cell adhesion and apoptosis of T cells and Ewing’s sarcoma (ES) cells, two cell types with a high level of CD99 expression. Engagement of the molecule induces a rapid death signal that appears to be related to the level of expression of this antigen. The rapid apoptosis induced by agonistic anti-CD99 monoclonal antibodies is of clinical interest in ES, a tumour for which no new drugs have been described as clearly effective in the last 10 years. In this study, we show that an anti-CD99 monoclonal antibody can be used to advantage in association with doxorubicin. Striking effectiveness was observed against local tumours and metastases. No remarkably toxic effects of anti-CD99 monoclonal antibody were found in bone marrow against blood precursors. These results provide the necessary rationale and support for a novel modality of therapeutic intervention, which may have application in the care of patients with ES.
K. Scotlandi, S. Perdichizzi, G. Bernard, G. Nicoletti, P. Nanni, P.-L. Lollini, et al. (2006). Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma. EUROPEAN JOURNAL OF CANCER, 42, 91-96 [10.1016/j.ejca.2005.09.015].
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma
SCOTLANDI, KATIA;NICOLETTI, GIORDANO;NANNI, PATRIZIA;LOLLINI, PIER LUIGI;CURTI, ANTONIO;PICCI, PIERO
2006
Abstract
CD99 is a 32 kDa surface glycoprotein that is involved in the migration of leukocytes, cell–cell adhesion and apoptosis of T cells and Ewing’s sarcoma (ES) cells, two cell types with a high level of CD99 expression. Engagement of the molecule induces a rapid death signal that appears to be related to the level of expression of this antigen. The rapid apoptosis induced by agonistic anti-CD99 monoclonal antibodies is of clinical interest in ES, a tumour for which no new drugs have been described as clearly effective in the last 10 years. In this study, we show that an anti-CD99 monoclonal antibody can be used to advantage in association with doxorubicin. Striking effectiveness was observed against local tumours and metastases. No remarkably toxic effects of anti-CD99 monoclonal antibody were found in bone marrow against blood precursors. These results provide the necessary rationale and support for a novel modality of therapeutic intervention, which may have application in the care of patients with ES.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
